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Abstract
The carbohydrate-deficient glycoprotein or CDG syndromes (OMIM 212065) are a recently delineated group of genetic,
multisystem diseases with variable dysmorphic features. The known CDG syndromes are characterized by a partial
deficiency of the N-linked glycans of secretory glycoproteins, lysosomal enzymes, and probably also membranous
glycoproteins. Due to the deficiency of terminal N-acetylneuraminic acid or sialic acid, the glycan changes can be observed in
serum transferrin or other glycoproteins using isoelectrofocusing with immunofixation as the most widely used diagnostic
technique. Most patients show a serum sialotransferrin pattern characterized by increased di- and asialotransferrin bands
(type I pattern). The majority of patients with type I are phosphomannomutase deficient (type IA), while in a few other
patients, deficiencies of phosphomannose isomerase (type IB) or endoplasmic reticulum glucosyltransferase (type IC) have
been demonstrated. This review is an update on CDG syndrome type IA. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The CDG syndromes are a family of genetic dis-
orders characterized by a de¢ciency of the glycan
moiety of glycoproteins. Only defects in N-glycan
synthesis have been characterized in CDG syndromes
to date. The synthesis of N-glycans occurs over three
cellular compartments: a cytosolic compartment, the
endoplasmic reticulum (ER) and the Golgi appara-
tus. Some forty (enzymatic and transport) steps are
involved. The ¢rst part of this pathway comprises the
synthesis of guanosine diphosphate (GDP)-mannose
from fructose 6-phosphate, an intermediate of the
glycolytic pathway. On the cytoplasmic side and sub-
sequently on the lumenal side of the ER a dolichyl-
pyrophosphate oligosaccharide (Dol-pyrophosphate-
GlcNAc2-Man9-Glc3) precursor is gradually as-
sembled. Subsequently, the oligosaccharide moiety
is transferred to selected asparagines of nascent pro-
teins by the oligosaccharyltransferase complex. In the
third part, the three glucoses and six mannoses are
removed and replaced by two or more residues each
of N-acetylglucosamine, galactose and sialic acid, in
that order, in the Golgi apparatus. In some glyco-
proteins (lysosomal enzymes) only the three glucose
residues are removed and the resulting glycoproteins
retain a high number of mannoses on most of their
glycans. This is followed by phosphorylation of man-
noses, binding of the enzymes to mannose 6-phos-
phate (Man6P) insulin-like growth factor II receptors
and uptake in the lysosomes [1,2].
Glycans are very important for the metabolism,
structure and function of glycoproteins and other
glycoconjugates [2^4] as evidenced by the severe dis-
eases resulting from defects in their synthesis. The
discovery of these diseases was based on the obser-
vation by Jaeken et al. [5] of unusual serum protein
abnormalities in the two princeps patients, namely, a
decrease of thyroxine-binding globulin and an in-
crease of arylsulfatase A activity. The search for a
defect as a common feature of these and other pro-
teins ¢nally attracted attention to the glycan moiety
since sialic acid de¢ciency in serum transferrin was
strongly suggested by isoelectrofocusing (IEF) [6]. As
of October 1998, about 280 patients world-wide
(published and unpublished) were known to the au-
thors [7^23]. IEF of serum transferrin remains the
cornerstone of the diagnosis of these diseases [6].
De¢ciency of the terminal, negatively charged sialic
acid results in a cathodal shift of the IEF pattern.
Three diseases associated with a type I pattern have
been well characterized at the enzymatic level : phos-
phomannomutase (PMM) and phosphomannose iso-
merase (PMI) de¢ciency (CDGS type IA and type
IB, respectively), both pre-endoplasmic reticulum
(ER) disorders, and ER glucosyltransferase de¢-
ciency (CDGS type IC; also called type V). In a
considerable number of patients, the basic defect still
remains to be determined. This review is limited to
CDGS type IA.
2. Clinical presentation
CDGS type IA occurs world-wide [24^28] and af-
fects both sexes equally [29]. There exists a great
variability in clinical expression even among a¡ected
siblings. The clinical presentation includes three main
features: a moderate to severe neurological disease, a
more-or-less typical dysmorphy, and a variable in-
volvement of di¡erent organs. The diagnosis can be
made in the ¢rst days of life. The neurological pic-
ture comprises abnormal slow rolling horizontal or
vertical eye movements combined with slow head
movements in the neonatal period, alternating inter-
nal strabismus, axial hypotonia and hypore£exia.
Later, ataxia as well as a marked psychomotor re-
tardation generally becomes obvious [20]. After in-
fancy, retinitis pigmentosa [30,31], joint contractures,
stroke-like episodes (in about 50% of the cases), and
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sometimes epilepsy develop. During the ¢rst year(s)
of life there are variable feeding problems that can
result in severe failure to thrive and that can neces-
sitate nasogastric tube feeding or feeding via gastro-
stomy [32].
A minority of infants have severe organ problems,
such as liver failure, cardiac insu⁄ciency, nephrotic
syndrome or multiorgan failure [17,33^35]. Together
with severe infections, these are the main causes of
death. Overall mortality is about 20% occurring
mostly in the ¢rst years of life. Some adults show
striking premature aging [36]. Only rarely do these
patients achieve walking without support, but, as a
rule there, is no regression. Their IQ ranges from
40 to 60 and they mostly have an extrovert and
cheerful personality.
3. Biochemical features
3.1. Glycoprotein abnormalities
Numerous glycoproteins demonstrate an abnormal
protein heterogeneity. In serum, data have been re-
ported on transport proteins [5,6,37^39], coagulation
and anticoagulation factors [37^44], hormones [5,45^
47], lysosomal and other enzymes [5,48^52], as well
as glycoproteins [37,53^58]. Information is also avail-
able on glycoproteins in cerebrospinal £uid [6,59,60],
leukocytes [48], ¢broblasts and liver [56,61]. Most
glycoprotein concentrations or enzyme activities in
serum are decreased; others are increased (e.g. sev-
eral lysosomal enzyme activities [48]) or normal (e.g.
transferrin, immunoglobulins [62]).
Human serum transferrin is involved in iron me-
tabolism; it contains 679 amino acid residues and
has a molecular mass of 75 143 kilodalton (kDa)
with an N-terminal domain (residues 1^336) and a
C-terminal domain (residues 337^679). There are
two glycosylation sites located on residues 413 and
611 with mostly biantennary N-acetyllactosamine-
type glycans [63,64] and a small amount of tri- and
tetra-antennary N-acetyllactosamine type glycans
[65,66]. Due to the heterogeneity of the glycan struc-
tures [67], serum transferrin consists of a pool of
glycovariants detectable by immuno-isoelectrofocus-
ing [68] using monospeci¢c anti-transferrin antibody.
Table 1A and B list the glycovariant composition of
transferrin (%) in control sera (n = 96) and serum of
CDGS type IA patients (n = 26), respectively. Data
were obtained by IEF of iron-saturated transferrin
separated on agarose gels in a pH gradient 5.0^7.0
using the Pharmacia PhastSystem followed by densi-
tometry. Prominent asialo- and disialotransferrins
and decreased tetra-, penta- and hexasialotransfer-
rins are observed in the patients sera [6,25,37,
54,56]. Mono- and trisialotransferrin composition re-
main unchanged.
Electrospray ionization-mass spectrometry (ESI/
MS) of whole serum transferrin from CDGS type
IA patients revealed both the normal and a smaller
glycovariant that correlated with tetra- and disialo-
Table 1
Percentile values and range of sialotransferrin fractions (expressed as %) in serum from control patients (A, n = 96), and patients with
CDG syndrome type IA (B, n = 26) as indicated by the number of sialic acids per transferrin molecule
0 1 2 3 4 5 6
(A)
P25 0 0 2.9 8.6 52.8 20.7 4.3
P50 0 1.1 3.5 9.8 55.9 22.7 5.1
P75 0 2.5 4.1 12 59.3 25.6 6.1
Range 0^1.4 0^5.3 1^7.2 3.7^17.1 45.8^72.9 10.2^29.9 0^9
(B)
P25 5.6 1.5 27.7 8.6 28.3 6.8 0.3
P50 8.5 2.3 30.9 10.8 34.8 9.3 1.6
P75 13.8 3.6 34.7 12 39.7 12 2.6
Range 1.7^28.5 0^5.1 14.3^37.1 6.4^18.7 17.5^56.5 5.3^17 0^5.5
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transferrin [69]. This was con¢rmed by Yamashita et
al. [70,71] who also demonstrated by ESI/MS that
the non-glycosylation site in the disialotransferrin
isoform was not speci¢c. Complex oligosaccharide
isomers can be analyzed as 9-aminopyren-1,4,6-tri-
sulfonate (APTS) derivatives by capillary electropho-
resis with laser-induced £uorescence detection [72].
Fig. 1A shows the electropherogram of APTS-la-
beled glycans obtained after enzymatic release from
200 Wg puri¢ed control serum transferrin in the pres-
ence of 2 nmol maltose (reference substance) accord-
ing to the eCAP N-linked Oligosaccharide Pro¢ling
Kit procedure (Beckman, USA). The arrow indicates
the main glycan fraction corresponding to the bian-
tennary glycan resulting from tetrasialotransferrin.
The electropherogram in Fig. 1B shows the APTS-
labeled glycans released from serum transferrin of a
CDGS type IA patient. The migration time of the
main glycan fraction with respect to maltose is the
same as in Fig. 1A suggesting a biantennary glycan
structure also for the disialotransferrin fraction
[70,71,73].
Remarkably, in serum of preterm infants with
PMM de¢ciency (postmenstrual age 6 37 weeks) a
normal IEF pattern of L-hexosaminidase, K1-anti-
trypsin, and transferrin has been observed [74].
3.2. Phosphomannomutase de¢ciency
N-Linked oligosaccharides on serum transferrin of
patients have a normal structure, but their total
number is decreased. This suggested a disturbance
in the ¢rst steps of the pathway comprising the syn-
thesis of GDP-mannose from fructose 6-phosphate
(Fig. 2), the formation of the dolichyl-pyrophosphate
oligosaccharide precursor or its transfer to the ac-
ceptor protein [69,71,75]. It was also found that ¢-
broblasts from patients with CDGS type IA incorpo-
rate less [3H]mannose into glycoprotein glycans and
contain truncated dolichol-linked oligosaccharide
precursors [75^78]. Defects in the synthesis of
Man6P from glucose [79], in the synthesis of dolich-
yl-phosphate and N-acetylglucosaminyl pyrophos-
phoryldolichol [80] as well as a de¢ciency of N-oli-
gosaccharyltransferase activity [81] were excluded.
Finally, phosphomannomutase (PMM) de¢ciency
was identi¢ed [82] (Fig. 2). This defect causes a re-
duced production of mannose 1-phosphate (Man1P),
GDP-mannose, GDP-fucose and dolichyl-phospho-
mannose, but not an increase of the substrate
Man6P [77,83]. Moreover, mannose levels are re-
duced in serum of these patients [84]. It seems that
approximately 80% [26,85] of the CDSG type I pa-
tients have PMM de¢ciency.
It has been shown recently that in rat [86,87] as
well as in man two di¡erent PMM isozymes exist :
PMM1, encoded by chromosome 22q13 [88^90] and
PMM2, encoded by chromosome 16p13 [91]. They
share about 66% sequence identity and are homolo-
gous to PMMs from S. cerevisiae (also known as
SEC53) and C. albicans.
Fig. 1. Capillary gel electrophoretic separation of maltose
(reference substance) and the N-linked oligosaccharides released
from serum transferrin by the eCAP N-linked Oligosaccharide
Pro¢ling Kit procedure (Beckman, USA). Arrows indicate the
main glycan fraction for a control (A), and a type IA patient
(B). (See text.)
BBADIS 61878 10-9-99
H. Carchon et al. / Biochimica et Biophysica Acta 1455 (1999) 155^165158
Human PMM1 and PMM2 have been overex-
pressed in E. coli and their kinetic properties have
been investigated [86^88]. Like most phosphomu-
tases, eukaryotic PMMs require a bisphosphate co-
factor (1,6-bisphosphate of glucose or mannose in
the case of PMM), that phosphorylates the catalytic
site. Man6P is ¢rst converted into mannose 1,6-bis-
phosphate which is then transformed into Man1P.
Human PMM, as well as yeast PMM are homo-
dimers with subunits of 30 kDa [86,92]. The human
PMM1 and the yeast PMM have approximately
equal activity in converting glucose 1-phosphate to
glucose 6-phosphate as in converting Man1P to
Man6P, whereas PMM2 acts 20 times more rapidly
as a phosphomannomutase than as a phosphogluco-
mutase [87]. In addition, PMM1 though not PMM2,
acts as a hexose 1,6-bisphosphatase which hydrolyzes
both mannose 1,6-bisphosphate and glucose 1,6-bis-
phosphate at a rate corresponding to about 3% of
its mutase activity. PMM2 is therefore more speci¢c
than PMM1, both in terms of substrate recognition
and in the kind of reaction that is catalyzed. PMM2
also has a signi¢cantly higher a⁄nity for its hexose
bisphosphate cofactor than PMM1 [86].
The distributions of PMM1 and PMM2 in di¡er-
ent tissues have been studied in rat, based on di¡er-
ences in their kinetic properties as well as on their
reactivity to antibodies raised against the two human
isozymes. PMM1 activity appears to be more re-
stricted to the brain and to the lungs, where it con-
stitutes about 65 and 10%, respectively, of the total
PMM activity. PMM2, however, is more widely dis-
tributed and appears to be responsible for more than
97% of the activity in other tissues, including cere-
bellum [87]. The ¢nding that the PMM activity of
one patient with CDGS type IA was below the de-
tection level both in liver and in skeletal muscle
argues also for PMM2 being the only isozyme ex-
pressed in these two tissues in man (Van Schaf-
tingen, unpublished data).
The ¢nding of very low activities (6 5% of the
normal activity) in liver, leukocytes, ¢broblasts or
lymphoblasts of the majority of patients with
CDGS type IA indicates that most of the mutations
are particularly severe, a ¢nding which is likely con-
¢rmed by observations on mutant proteins expressed
in bacterial systems [87]. In some patients, activities
were up to 25% higher in ¢broblasts or lymphocytes
than in leukocytes [26,93]. It is not known presently
whether this high activity in ¢broblasts or lympho-
blasts results from abnormal expression of PMM1 or
from overexpression of a partially active enzyme.
4. Molecular biology of the PMM2 gene
CDGS type IA is inherited in an autosomal reces-
sive manner and the gene has been localized to chro-
mosome 16p13 by linkage analysis [94,95]. Fine map-
ping of the disease locus was obtained by haplotype
and linkage disequilibrium analysis in Scandinavian
families [96]. By observing critical cross-overs in car-
riers identi¢ed by measuring PMM activities in sib-
lings of patients, Schollen et al. [97] located the gene
between markers D16S404 and D16S406. The iden-
ti¢cation of the PMM2 gene on chromosome 16p13
and the identi¢cation of mutations in this gene that
segregate with the disease [91] gave ¢nal support to
the biochemical evidence that PMM de¢ciency is the
basis for CDGS type IA [24,82]. The human PMM2
gene [91] and the PMM1 gene (OMIM 601786) [88]
were identi¢ed on the basis of the sequence similarity
Fig. 2. Part of the N-glycosylation pathway. Vertical bar indicates the location of PMM de¢ciency.
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of a number of expressed sequence tags (ESTs) in the
public database with the sequence of yeast PMM or
SEC53. The cDNA of PMM2 has an open reading
frame of 738 base pairs and encodes a protein of 246
amino acids. The protein has been expressed in vitro,
and shown to have PMM activity. The degree of
identity with yeast SEC53 is slightly higher for
PMM2 than for PMM1 [88,91]. The PMM2 gene
consists of eight exons spanning approximately 20
kilobases of genomic DNA [91,97]. An analysis of
the sequence of the 5P region of the gene suggests
that PMM2 has a housekeeping promoter; which is
expected for an enzyme with a very fundamental role
in post-translational processing. However, the varia-
ble expression suggests that the basal expression can
be modulated in a tissue-speci¢c manner.
Molecular analysis of the PMM2 gene has led to
the identi¢cation of a large number of mutations
which are generally of the missense type ([91,93], T.
Martinsson; N. Seta; V. Cormier-Daire, unpublished
data). The mutations are numbered according to
their position in the cDNA (Genbank accession no.
85773) [91] (Fig. 3).
The most intriguing observation is the total lack of
patients homozygous for the most frequent muta-
tion: R141H [93] (T. Martinsson, unpublished
data). On the other hand, patients homozygous for
the relatively frequent F119L mutation were found
[93,98] as well as one patient homozygous for the
D65Y mutation [93]. Thus, it is suggested that the
R141H mutation is a severe mutation, and homo-
zygosity may not be compatible with life. It might
also give rise to a di¡erent phenotype or no pheno-
type at all.
Due to the extensive allelic heterogeneity revealed
by the mutation analysis, only limited inferences can
be made from the genotype^phenotype comparison.
There is no clear correlation between the PMM ac-
tivities and the genotype in 6 and 14 patients with the
R141H/P113L and R141H/F119L combinations, re-
spectively. A remarkable observation is the high
mortality in the patients with the D188G/R141H
genotype where four of ¢ve patients died before the
age of 2 years, while the ¢fth patient, now 10 years of
age, is severely a¡ected. The twin patients described
originally [5] are now 22 years old and relatively well,
and have the R141H/P113L genotype. The R123G
mutation is observed in two Spanish patients with
pubertal development, which is not normally seen
in CDGS type IA. There is a relatively high residual
PMM activity in ¢broblasts of the D65Y/D65Y pa-
tient [93]. However, the same D65Y mutation, in
combination with the R141H mutation was found
in a patient with a severe phenotype, who died at a
very young age [93]. There is emerging data on adult
cases of CDGS type IA. A 35-year-old patient, with
a typical history of CDGS type IA was homozygous
for the F119L mutation [93,98]. French investigators
identi¢ed two patients 30 and 33 years of age with
the C9Y/R141H genotype (N. Seta; V. Cormier-
Daire, unpublished data).
Northern analysis of human tissues showed high-
Fig. 3. Schematic diagram of PMM2 cDNA, indicating the various mutations found in the gene on the exons. Mutations that have
been relatively frequently encountered are indicated in boxes bordered by the thicker lines.
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est expression of the PMM2 gene in pancreas and
liver, two organs that both have a high production
of secreted proteins. The gene is also expressed in
kidney and placenta, and to a lesser extent in skeletal
muscle and heart, and weakly in brain. On Northern
blots, no expression is detected in lung [91]. The ex-
pression pattern of PMM1 is di¡erent from the pat-
tern obtained for PMM2. In brain PMM1 is highly
expressed [88]. It is not clear at present how these
levels of expression would correlate to the clinical
picture, in which brain is one of the most severely
a¡ected organs. Immunohistological data are not
available yet.
In the course of the mapping experiments, a pro-
cessed pseudogene was identi¢ed on chromosome 18
[97] that closely related to PMM2. When compared
to PMM2, several base substitutions and single base
insertions or deletions are present, suggesting that
this processed pseudogene (PMM2i) has been inac-
tivated by mutations. Remarkably, several base sub-
stitutions in PMM2 that are associated with disease,
are also present at the corresponding positions in the
PMM2i. Thus, mutations that occur at a slow rate
in the active gene in the population have also accu-
mulated in the processed pseudogene. This is an im-
portant observation, because these mutations might
interfere with certain mutation detection strategies,
e.g. dot blot analysis. Therefore probes need to be
designed carefully.
5. Diagnosis
The CDGS type IA is diagnosed by IEF and im-
muno¢xation of serum transferrin [6,25] or transfer-
rin obtained from dried blood spots [99] (Table 1B).
When an abnormal pattern is observed, IEF of an-
other glycoprotein (e.g. L-hexosaminidase, thyroxine-
binding globulin) is required to eliminate protein var-
iation [100]. Further con¢rmation should be obtained
by ¢nding decreased PMM activity in leukocytes or
¢broblasts [26,78,82]. It must be kept in mind that
cord sera from controls show increased asialo-,
mono- and disialotransferrin fractions [101]. A satu-
ration by iron is required to produce the typical IEF
pattern [102]. EDTA plasma can produce deviating
patterns [19], only serum or heparin plasma should
be used. The determination of carbohydrate-de¢cient
transferrin (CDT) in also used as screening test. This
method, initially developed for diagnosing alcohol
abuse, measures the total concentration of cathodal
isotransferrins in serum, while the normal compo-
nents are retained by the anion exchanger. In this
case, the microanion exchange chromatography of
transferrin is followed by a transferrin radioimmuno-
assay of the eluate [103,104]. Except when rare ge-
netic D variants of transferrin are present, increased
concentrations of CDT indicate a reduction of its
sialic acid content [52,105]. However, the CDT test
provides only limited information for the diagnosis
of CDG syndromes because the distribution of the
abnormal glycovariants remains unknown.
A diagnosis of CDGS type IA should be com-
pleted by mutational analysis. Given the frequency
of the R141H, F119L and P113L mutations, the ob-
vious approach is to search for these mutations ¢rst.
Due to this heterogeneity, PMM assays are still use-
ful for diagnosis. However, in some cases, the activ-
ity found in ¢broblasts or in lymphoblasts still rep-
resents up to about 30% of the control value,
whereas in other samples derived from the same pa-
tients or from other patients with the same genotype,
the activity was less than 5% of the control activity
[93]. This problem has not been encountered in as-
says performed with fresh material such as leuko-
cytes or liver. In the latter cases, a profound de¢-
ciency has nearly always been observed. PMM
measurements are also useful for the identi¢cation
of carriers. If cells from an a¡ected child are not
available, indirect evidence can be obtained from
the PMM activities in leukocytes from the parents
[106]. In view of the genetic heterogeneity, prenatal
testing should only be o¡ered to families with a
documented PMM de¢ciency and mutations in
PMM2.
6. Conclusion
No e⁄cient treatment is available at present.
Although mannose is able to correct glycosylation
in vitro in ¢broblasts with PMM de¢ciency
[77,107,108], in vivo trials with oral and intravenous
mannose did not cause any clinical or biochemical
improvement [19,109^111].
CDGS type IA has a broad phenotype. Recently, a
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female CDGS type IA patient presented with ap-
proximately 10% of the normal PMM activity, but
with very mild clinical symptoms [112]. Extensive
screening is therefore recommended by performing
serum sialotransferrin IEF analysis also in patients
with only mild psychomotor retardation and no or
only minor dysmorphy.
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